Skip to main content

Recent Publications

Browse recent studies from the Lou and Jean Malnati Brain Tumor Institute to learn more about our cutting-edge research.

  1. Song R, Liu L, Ofori-Apau J, Hojo E, Mirza M, Huston J, Gondi V, Khan OH  The clinical utility of magnetic resonance elastography in differentiating tumor recurrence from pseudoprogression in glioblastoma.  Magn Reson Imaging  2026 Nov;133:110746. doi:10.1016/j.mri.2026.110746
  2. Huang ZL, Jiang T, Suarez Palacios MM, Ouyang T, Abdallah A, Niu L, Chen J, Zhai X, Ciolak E, Qiang W  et al.  Therapy-associated lineage plasticity in DIPG following combined CDK4/6 inhibitor, temozolomide, and radiation.  Cancer Lett  2026 Oct 28;659:218771. doi:10.1016/j.canlet.2026.218771
  3. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E  et al.  Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).  J Clin Oncol  2026 Oct 10;44(29):2800-2810. doi:10.1200/JCO-25-02735
  4. Drewes NB, Xu Y, Kumthekar PU, Ahmed AU  Purine Metabolism as a Therapeutic Target in Glioblastoma.  Hematol Oncol Clin North Am  2026 Oct 09;. pii:S0889-8588(26)00112-7
  5. Asogwa OA, Dirven L, van den Bent MJ, Aaronson NK, Baumert BG, Brandes AA, Clement PM, Coens C, Gorlia T, Herrlinger U  et al.  Health-Related Quality of Life in Glioma Subtypes: A Pooled Analysis of 16 Randomized Trials from the CODAGLIO 2.0 project.  Neuro Oncol  2026 Oct 01;. pii:noag231
  6. Congivaram H, Thirunavu V, Santana-Santos L, Jamshidi P, Arendhsen JT, Castellani RJ, Brat DJ, Cooper LAD, Ayad MA, Chen WC  et al.  An evidence-based workflow for integrating molecular testing with histopathology in the workup of meningiomas.  Neuro Oncol  2026 Oct 01;. pii:noag217
  7. Evageliou NF, Renfro LA, Vallance KL, Varela CR, Benedetti DJ, Cost NG, Ehrlich PF, Kalapurakal JA, Khanna G, Aldrink JH  et al.  Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.  Cancer  2026 Oct 01;132(19):e70610. pii:e70610
  8. Zhang S, Singh O, Dazelle K, Quezado M, Cimino PJ, Abdullaev Z, Wu J, Lucas CH, Schreck KC, Holdhoff M  et al.  High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort.  Neuro Oncol  2026 Oct 01;28(10):2435-2448. doi:10.1093/neuonc/noag145
  9. Wang P, Wang J, Wang Q, Youngblood MW, Cheng Y, Tao B, Wong JH, Luan Y, Yu S, Swaroop A  et al.  Spatial chromatin architecture and accessibility co-profiling of mammalian tissues.  Nat Methods  2026 Oct;23(10):2015-2028. doi:10.1038/s41592-026-03217-4
  10. Piña Y, Umeh Garcia M, Boire A, Brenner A, Camidge DR, Chang S, Forsyth PA, Hayden Gephart M, Olayinka Kamson D, Kumthekar P  et al.  Breaking barriers in leptomeningeal disease: A Society for Neuro-Oncology and The American Society of Clinical Oncology consensus review on clinical trial design and basic science integration.  Neuro Oncol  2026 Oct 01;28(10):2299-2312. doi:10.1093/neuonc/noag126
  11. Lee C, Mille MM, Griffin KT, Rigsby C, Popescu A, Gopalakrishnan M, Leisenring W, Peterson S, Dome JS, Laurie F  et al.  Estimation of Detailed Cardiac Doses for Pediatric Radiation Therapy Patients in National Wilms Tumor Study.  Int J Radiat Oncol Biol Phys  2026 Oct 01;126(2):359-370. doi:10.1016/j.ijrobp.2026.04.006
  12. Benato A, Du R, Kemeny H, Wolinsky JP  En Bloc Resection for Primary Malignant Tumors of the Subaxial Cervical Spine: Oncologic and Technical Considerations.  Clin Spine Surg  2026 Sep 28;. doi:10.1097/BSD.0000000000002187
  13. Núñez FJ, Banerjee K, Mujeeb AA, Mauser A, Tronrud CE, Zhu Z, Raghuram S, Sheth MR, Pena Agudelo JA, Zelaya J  et al.  Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.  Nat Commun  2026 Sep 18;17(1). pii:9740
  14. Sharma A, Johnson M, Kim H, Kumthekar P, Yogendran LV, Siegel C, Lwin Z, Koekkoek JAF, Leng LZ, Balogun J  et al.  Neuropalliative care in brain cancer.  Clin Med (Lond)  2026 Sep 18;26(5):100645. doi:10.1016/j.clinme.2026.100645
  15. Kundu IG, Toro N, Mochizuki AY, Langhnoja J, Ayyagari RV, Cronk JC, Reel SM, Arounleut P, Tron Esqueda LE, Fuller CE  et al.  Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.  Neuro Oncol  2026 Sep 17;. pii:noag228
  16. Abdullah KG, Miki K, Edgar CK, Wu SA, Xiao Y, Huang YT, Drexler R, Krishna S, Puliyappadamba VT, Tay LWR  et al.  Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth.  Cell  2026 Sep 15;. pii:S0092-8674(26)01010-X
  17. Sehrawat K, Polley MC, Vogelbaum MA, Gilbert M, Chakravarti A, Cahill DP, Lassman AB, Raleigh DR, Sulman EP, Machtay M  et al.  The evolution of RTOG and NRG Oncology CNS tumors clinical trials.  J Neurooncol  2026 Sep 15;179(2). pii:83
  18. He Q, Wu R, Yu X, Song X, Walker M, Tiek D, Jiang T, Li XN, Her C, Hu B  et al.  EFTUD2-Regulated Alternative Splicing of MSH5 Drives Radioresistance in Recurrent IDH-Mutant Glioma.  Neuro Oncol  2026 Sep 09;. pii:noag225
  19. Machingura A, Weller J, Koekkoek JAF, Dirven L, Preusser M, Roth P, Stupp R, Weller M, Pe M, Gorlia T  et al.  Association between temozolomide-related hematologic toxicity and health-related quality of life (HRQoL) in patients with newly diagnosed glioblastoma.  Neuro Oncol  2026 Sep 08;. pii:noag224
  20. Brat DJ, van den Bent MJ  Recommendations in cIPMACT-NOW Update 12 Should Identify Grade 2 IDH-Mutant Astrocytoma Patients with Truly Low Risk Disease by Pathology.  Neuro Oncol  2026 Sep 04;. pii:noag216
  21. Yu X, Wu R, Huang T, Tiek D, Walker M, He Q, Horbinski C, Hu B, Cheng SY  EGFR-co-amplified lncRNA ELDR drives glioblastoma tumorigenicity by enhancing BMI1 activity.  Neuro Oncol  2026 Sep 03;. pii:noag213
  22. Gaikwad H, Angarita D, Carter N, Reichardt N, Siegel D, Mattanovich H, De Melo DM, Anchordoquy TJ, Aguado J, Graner A  et al.  Physicochemical and molecular determinants of lipid migration through multicellular assemblies.  J Control Release  2026 Sep 02;399(Pt A):115326. doi:10.1016/j.jconrel.2026.115326
  23. Pang L, Liu Y, Zhou F, Guo S, Khan F, Ali H, Shah H, Huber S, Kofler B, Horbinski CM  et al.  Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells.  Nat Cancer  2026 Sep;7(9):1387-1405. doi:10.1038/s43018-026-01221-3
  24. Yu X, Wu R, Cheng SY  Sequential EGFR inhibition sensitizes glioblastoma to temozolomide.  Trends Pharmacol Sci  2026 Sep;47(9):952-954. doi:10.1016/j.tips.2026.07.010
  25. Radaelli S, Frezza AM, Fossati P, Baldi GG, Akiyama T, Asencio JM, Bolle S, Bovee JVMG, Caraceni AT, Cote GM  et al.  Global Consensus on the Management of Primary Localized Chordoma.  JAMA Oncol  2026 Sep 01;12(9):1018-1026. doi:10.1001/jamaoncol.2026.2054
  26. Li X, Xu J, Du G, Jia X, Zhao D, Zhou C, Xiao K, Gu J, Zhu J, Shang X  Accurately Deciphering Tissue Heterogeneity From Spatial Multi-Modal and Multi-Omics With STransformer.  Adv Sci (Weinh)  2026 Sep;13(49):e75969. pii:e75969
  27. Wang Y, Belakhoua S, Yang Y, Serrano J, Horbinski C, Boué DR, DeWitt JC, Liechty B, McGuone D, Mao Q  et al.  Histopathological and molecular heterogeneity of dysembryoplastic neuroepithelial tumors.  J Neuropathol Exp Neurol  2026 Sep 01;85(9):1033-1040. doi:10.1093/jnen/nlag052
  28. Brat DJ, Aldape K, French PJ, Louis DN, Nasrallah MP, Reifenberger G, Reuss DE, Touat M, van den Bent MJ, Wesseling P  et al.  cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.  Neuro Oncol  2026 Sep 01;28(9):2069-2089. doi:10.1093/neuonc/noag108
  29. Chojak R, Turunen JR, Drewes NB, Koutah L, Fares J, Chen RX, Du R, Faisal UH, Kazi HA, Kelley C  et al.  The intersection of chemokine signaling with the hallmarks of cancer in glioblastoma.  J Neurooncol  2026 Aug 26;179(2). pii:55
  30. Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M, Bommi P, Dixit K, Kumthekar P, Sharp L  et al.  Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.  Clin Cancer Res  2026 Aug 14;32(16):3476-3492. doi:10.1158/1078-0432.CCR-26-1124
  31. Tiwari A, Pawlowski KD, Balyasnikova IV  Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches.  Acta Neuropathol  2026 Aug 03;152(1). pii:15
  32. Li X, Zhao D, Jia X, Du G, Xu J, Qi Y, Chen Y, Wu Y, Gu J, Zhu J  et al.  Deciphering spatial heterogeneity by multimodal spatial transcriptomics modelling with SpatialModal.  Bioinformatics  2026 Aug 03;42(8). pii:btag540
  33. Chojak R, Drewes NB, Slychan K, Lukas RV  Spatial patterns of progression in reported glioblastoma cohorts after upfront chemoradiation and salvage therapy: a systematic review and meta-analysis.  J Neurooncol  2026 Jul 30;179(1). pii:20
  34. Xia Y, Papali P, Al-Mistarehi AH, Meyer C, Gross J, Khan M, Bettegowda C, Witham T, Bydon A, Theodore N  et al.  Detailing long-term functional morbidity after resecting mobile spine chordomas across 35 patients.  J Neurosurg Spine  2026 Jul 24;45(4):622-631. doi:10.3171/2026.2.SPINE251166
  35. Walker MN, Tang H, Silvers C, Roth S, Tiek D, Hu B, Cheng SY, Song X  iPSC-Derived Microglia-like Cells Exhibit Protocol-Dependent Transcriptomic Features and Robust Phagocytosis of Glioma Cells.  bioRxiv  2026 Jul 22;. pii:2026.07.21.739939
  36. Rashidi AP, Perronne L, Krumpelman C, Hill V, Borhani AA, Subedi K, Kelahan L, Avery R, Savas H, Rusinak D  et al.  Physics-Informed Multiscale Decoding of Tissue Microstructure: The Gray Level Affinity Metrics (GLAM) Framework.  J Imaging Inform Med  2026 Jul 20;. doi:10.1007/s10278-026-02132-6
  37. Li J, Wang X, Tong L, Feng B, Shih LK, Markwell SM, Nuszen H, Gruchala T, Lam NG, Basakis P  et al.  The perinecrotic niche of glioblastoma drives tumor-associated macrophage polarization and immunosuppression via podoplanin-mediated CLEC5A activation.  J Clin Invest  2026 Jul 15;136(14). pii:e199228
  38. Huang S, Lian Z, Jia D, Sun K, Li X, Liu J, Wang Y, Jiang C, Zhu F, Ding Z  et al.  BrainSeg: a generalized framework for comprehensive multimodal brain tissue segmentation, parcellation, and lesion labeling.  NPJ Digit Med  2026 Jul 10;. doi:10.1038/s41746-026-02894-x
  39. Eshac Y, Cabang J, Miska J  The brain's sweet spot: why microglia can run on fructose metabolism.  Front Immunol  2026;17:1864729. pii:1864729
  40. Singh R, Koempel A, French B, Crawford C, Perlow HK, Rauh S, Kutuk T, Beyer S, Grecula J, Blakaj D  et al.  Improved Progression-Free Survival Following Dose-Escalated Versus Standard-Dose Postoperative Radiation Therapy for High-Risk Meningiomas: An International Multicenter Individual Patient-Level Meta-Analysis (FIRESTORM).  Int J Radiat Oncol Biol Phys  2026 Jul 01;125(3):696-705. doi:10.1016/j.ijrobp.2026.03.036
  41. Weber-Levine C, Xia Y, Al-Mistarehi AH, Jiang K, Mendelson BZ, Antar A, Ksabi NL, Zaitoun KJ, Papali P, Neerumalla S  et al.  The Impact of Expansile Duraplasty After Resection of Intramedullary Astrocytomas.  Oper Neurosurg  2026 Jul 01;31(1):36-49. doi:10.1227/ons.0000000000001762
  42. Kim KS, Zhang J, Arrieta VA, Dmello C, Grabis E, Yabo YA, Wang S, Habashy K, Duffy J, Zhao J  et al.  Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses.  Nat Commun  2026 Jun 25;17(1). pii:7968
  43. Ozer BH, Lindhorst SM, Merrell RT, Trevino CR, Rudnick JD, Avgeropoulos NG, Ramakrishna N, Khagi S, Rauf Y, Walbert T  et al.  Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.  medRxiv  2026 Jun 24;. pii:2026.06.22.26354817
  44. Walker MN, Hu B, Cheng SY, Song X  Stepwise Protocol for Alternative Splicing Analysis in Single-Cell SMART-Seq2 RNA-Seq Data.  Bio Protoc  2026 Jun 20;16(12):e5735. pii:e5735
  45. Nathan CL, Ghandour D, Cunningham EM, Lukas RV, Sullivan J, Sachdev S, Templer JW  Epilepsy characteristics and outcomes in patients with pleomorphic xanthoastrocytomas.  J Neurooncol  2026 Jun 19;178(3). pii:72
  46. Mooney R, Ngai G, Kaur G, Kang EY, Lara J, Abd El-Fattah EE, Huang P, Flores L, McDonald M, Talley M  et al.  Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.  Mol Ther Oncol  2026 Jun 18;34(2):201219. pii:201219
  47. Fares J, Ahrendsen JT, Congivaram HT, Santana-Santos L, Oyon D, Dixit K, Youngblood MW, Chandler JP  CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor.  Discov Oncol  2026 Jun 17;17(1). pii:1251
  48. Khalifeh JM, ElNemer W, Ghaith AK, Khalilullah T, Rajasekaran J, Xia Y, Ahmed AK, Azad TD, Yang L, Al-Mistarehi AH  et al.  Surgical Management of Spinal Chondrosarcoma: Retrospective Case Series and Systematic Review of the Literature.  Oper Neurosurg  2026 Jun 03;. doi:10.1227/ons.0000000000002086
  49. Habashy KJ, Arrieta VA, Haupt B, Gómez M, El-Hajj VG, Kim KS, Dmello C, Chen L, Carpentier A, Canney M  et al.  Development of skull-implanted ultrasound for blood-brain barrier opening and drug delivery in neuro-oncology.  Neurooncol Adv  2026 Jun;8(Suppl 4):iv9-iv19. doi:10.1093/noajnl/vdaf044
  50. Mejia-Bautista M, Loxas M, Jamshidi P, Duckett D, Wolinsky JP, Ahrendsen JT  A 40-year-old woman with a spinal mass.  Brain Pathol  2026 Jun 01;:e70111. doi:10.1111/bpa.70111
These are the publications from our team members that have been most recently indexed by PubMed. Visit PubMed to see more of our publications.

Follow MBTI on FacebookYouTubeLinkedInInstagram